Journal of Clinical Oncology, Vol 21, Issue 23
(December), 2003: 4444-4454
© 2003 American Society for Clinical Oncology
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
Meletios A. Dimopoulos,
Athanasios Anagnostopoulos,
Donna Weber
From the Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; and Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Address reprint requests to Meletios A. Dimopoulos, MD, 227 Kifissias Ave, Kifissia, Athens 14561, Greece; e-mail: mdimop{at}med.uoa.gr.
Purpose: In 1999, investigators reported promising results of a phase II study of thalidomide in patients with resistant multiple myeloma (MM). Since then, various trials of thalidomide alone and in combination with other agents have been tested in patients with resistant and, more recently, untreated MM. In addition, preliminary results of phase I studies of the immunomodulatory derivatives (IMiDs) of thalidomide have been recently reported.
Design: We reviewed and report the results of clinical trials of thalidomide and the IMiDs, as well as the pharmacology, mechanism of action, and toxicity of these agents.
Results: Thalidomide has demonstrated significant activity in both resistant and previously untreated multiple myeloma. Combination therapy with dexamethasone increases response rate, even in patients previously resistant to both drugs given as single agents. More recent studies of thalidomide with dexamethasone in previously untreated patients are highly encouraging. The addition of chemotherapy to thalidomide and dexamethasone may further increase response rates, but its effect on patient survival has not been clarified. Preliminary results of trials of IMiD-3 indicate that this agent is active in resistant myeloma and has a toxicity profile different from that of thalidomide.
Conclusion: Many studies have confirmed the activity of thalidomide in MM, as well as an improved response with dexamethasone. Newer thalidomide derivatives with reduced toxicity (neuropathy, teratogenicity) are also promising. Thalidomide with dexamethasone may now represent the treatment of choice for previously untreated patients. Further studies with these and other novel agents early in the course of myeloma may improve complete remission rates and frequency of long-term control.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Correspondence
- Thalidomide With Continuous Low-Dose Dexamethasone for Multiple Myeloma
Joseph Gardyn
JCO 2005 23: 1323
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
K Zervas, D Mihou, E Katodritou, A Pouli, C. Mitsouli, A Anagnostopoulos, S Delibasi, M. Kyrtsonis, N Anagnostopoulos, E Terpos, et al.
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
Ann. Onc.,
August 1, 2007;
18(8):
1369 - 1375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Sosman and I. Puzanov
Molecular targets in melanoma from angiogenesis to apoptosis.
Clin. Cancer Res.,
April 1, 2006;
12(7):
2376s - 2383s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
J. Clin. Oncol.,
January 20, 2006;
24(3):
431 - 436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar, S. R. Hayman, M. Q. Lacy, A. Dispenzieri, S. M. Geyer, B. Kabat, S. R. Zeldenrust, S. Kumar, P. R. Greipp, R. Fonseca, et al.
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Blood,
December 15, 2005;
106(13):
4050 - 4053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar
Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1549 - 1551.
[PDF]
|
|
|
|
|
|
|
J. Blade, L. Rosinol, A. Sureda, J. M. Ribera, J. Diaz-Mediavilla, J. Garcia-Larana, M. V. Mateos, L. Palomera, J. Fernandez-Calvo, J. M. Marti, et al.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
Blood,
December 1, 2005;
106(12):
3755 - 3759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. Lane, D. Gill, P. N. Mollee, and S. V. Rajkumar
Role of VAD in the initial treatment of multiple myeloma
Blood,
November 15, 2005;
106(10):
3674 - 3675.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar and R. A. Kyle
Multiple Myeloma: Diagnosis and Treatment
Mayo Clin. Proc.,
October 1, 2005;
80(10):
1371 - 1382.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar
Multiple myeloma: the death of VAD as initial therapy
Blood,
July 1, 2005;
106(1):
2 - 3.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Z. Badros, O. Goloubeva, A. P. Rapoport, B. Ratterree, N. Gahres, B. Meisenberg, N. Takebe, M. Heyman, J. Zwiebel, H. Streicher, et al.
Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients
J. Clin. Oncol.,
June 20, 2005;
23(18):
4089 - 4099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Gardyn
Thalidomide With Continuous Low-Dose Dexamethasone for Multiple Myeloma
J. Clin. Oncol.,
February 20, 2005;
23(6):
1323 - 1323.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kyle and S. V. Rajkumar
Multiple Myeloma
N. Engl. J. Med.,
October 28, 2004;
351(18):
1860 - 1873.
[Full Text]
[PDF]
|
|
|
|
